Farmakologisk behandling av opioid- och kokainberoende - SBU
Farmakologisk behandling av opioid- och kokainberoende - SBU
Farmakologisk behandling av opioid- och kokainberoende - SBU
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Tabell I fortsättning<br />
Studie N Sidomiss- Preparat Psyk Beh<br />
bruk vid soc per<br />
inklusion beh veckor<br />
Johnson et al [23] 90 * 1. Buprenorfin 8 mg/d * 2<br />
1995 2. Buprenorfin 2 mg/d<br />
3. Placebo<br />
Johnson et al [24] 99 Kokain 1. Buprenorfin 8 mg/d ja 11<br />
1995 2. Buprenorfin 8 mg vad,<br />
placebo vad<br />
Schottenfeld 58 * 1. Metadon * 24<br />
et al [58,59] 2. Metadon<br />
1997 ⇒ 3. Buprenorfin 12 mg/d<br />
4. Buprenorfin 4 mg/d<br />
Ling et al [39] 736 ** 1. Buprenorfin 16 mg/d ja 16<br />
1998 (375) 2. Buprenorfin 8 mg/d<br />
3. Buprenorfin 4 mg/d<br />
4. Buprenorfin 1 mg/d<br />
BDI = Becks depression inventory, BL = Base line, BZD = Bensodiazepines, LAAM = Levo<br />
alpha acetyl methadol, OWRS = Opiate withdrawal rating scale, OWSC = Opiate withdrawal<br />
symptom checklist, WSC = Withdrawal symptom checklist, $ = US dollar, ( ) = Completers,<br />
212<br />
BEHANDLING AV ALKOHOL- OCH NARKOTIKAPROBLEM
Change language